Janus kinase inhibitors in patients with ankylosing spondylitis: Great news, but some concerns on cardiovascular disease risk still exist

Eur J Intern Med. 2022 Sep:103:107-108. doi: 10.1016/j.ejim.2022.05.033. Epub 2022 Jun 3.

Authors

Athina Dimosiari¹, Theodoros Michailidis², Dimitrios Patoulias³

Affiliations

¹ Department of Emergency Medicine, General Hospital "Hippokration", Thessaloniki, Greece.
² Second Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece.
³ Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Greece. Electronic address: [email protected].

PMID: 35667942
DOI: 10.1016/j.ejim.2022.05.033

No abstract available

Keywords: Ankylosing spondylitis; Cardiovascular disease; JAK inhibitors.

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases*
Case-Control Studies
Humans
Janus Kinase Inhibitors*
Spondylitis, Ankylosing*

Substances

Janus Kinase Inhibitors